Although more studies are needed to assess the safety and tolerability of ApoA1 and ApoA1 mimetic peptides at relevant doses for the anti-tumorigenic and chemosensitising effect, the potential translational application of this therapeutic approach is particularly promising (Foley et al., 2013; Miller et al., 2016) and the use of ApoA1 or a mimetic peptide in combination with conventional cytotoxic drugs might bring real benefits to women affected by ovarian cancer. This evidence concerns the gene APOA1 and ovarian carcinoma.